Latrepirdine increases cerebral glucose utilization in aged mice as measured by [18F]-fluorodeoxyglucose positron emission tomography

Neuroscience

Volumn 189, Issue , 2011, Pages 299-304

  Day, M ^a   Chandran, P ^a   Luo, F ^a   Rustay, N R ^a   Markosyan, S ^a   LeBlond, D ^a   Fox, G B ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Alzheimer's disease; Glucose metabolism; Latrepirdine; Mouse; PET

Indexed keywords

DIMEBON; FLUORODEOXYGLUCOSE F 18; GLUCOSE;

AGED; ANIMAL EXPERIMENT; ARTICLE; CEREBRAL GLUCOSE UTILIZATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; IN VIVO STUDY; MONITORING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

AGING; ANIMALS; BRAIN; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; INDOLES; MICE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 79960910783     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.05.032     Document Type: Article

References (41)

1. Alexander G.E., Chen K., Pietrini P., Rapoport S.I., Reiman E.M. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 2002, 159:738-745.
2. Ashe K.H., Zahs K.R. Probing the biology of Alzheimer's disease in mice. Neuron 2010, 66:631-645.
3. Bachurin S.O., Shevtsova E.P., Kireeva E.G., Oxenkrug G.F., Sablin S.O. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci 2003, 993:334-344. [discussion:345-339].
4. Bokde A.L., Pietrini P., Ibanez V., Furey M.L., Alexander G.E., Graff-Radford N.R., Rapoport S.I., Schapiro M.B., Horwitz B. The effect of brain atrophy on cerebral hypometabolism in the visual variant of Alzheimer disease. Arch Neurol 2001, 58:480-486.
5. Bouchier-Hayes L., Lartigue L., Newmeyer D.D. Mitochondria: pharmacological manipulation of cell death. J Clin Invest 2005, 115:2640-2647.
6. Chang D.T., Reynolds I.J. Mitochondrial trafficking and morphology in healthy and injured neurons. Prog Neurobiol 2006, 80:241-268.
7. Coleman P., Federoff H., Kurlan R. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology 2004, 63:1155-1162.
8. Constantinescu C.C., Mukherjee J. Performance evaluation of an Inveon PET preclinical scanner. Phys Med Biol 2009, 54:2885-2899.
9. Day M., Balci F., Wan H.I., Fox G.B., Rutkowski J.L., Feuerstein G. Cognitive endpoints as disease biomarkers: optimizing the congruency of preclinical models to the clinic. Curr Opin Investig Drugs 2008, 9:696-706.
10. de la Monte S.M., Luong T., Neely T.R., Robinson D., Wands J.R. Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease. Lab Invest, J Tech Methods Pathol 2000, 80:1323-1335.
11. de la Monte S.M., Wands J.R. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J Alzheimers Dis 2006, 9:167-181.
12. Dickerson B.C., Sperling R.A. Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. NeuroRx 2005, 2:348-360.
13. Doody R.S., Gavrilova S.I., Sano M., Thomas R.G., Aisen P.S., Bachurin S.O., Seely L., Hung D. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008, 372:207-215.
14. Ferreira I.L., Resende R., Ferreiro E., Rego A.C., Pereira C.F. Multiple defects in energy metabolism in Alzheimer's disease. Curr Drug Targets 2010, 11(10):1193-1206. Review.
15. Gambhir S.S., Czernin J., Schwimmer J., Silverman D.H., Coleman R.E., Phelps M.E. A tabulated summary of the FDG PET literature. J Nucl Med 2001, 42:1S-93S.
16. Hampel H., Frank R., Broich K., Teipel S.J., Katz R.G., Hardy J., Herholz K., Bokde A.L., Jessen F., Hoessler Y.C., Sanhai W.R., Zetterberg H., Woodcock J., Blennow K. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010, 9:560-574.
17. Hawkins R.A. Brain energy metabolism and function during hepatic encephalopathy. Eur J Clin Invest 1984, 14:313-314.
18. Hoffman J.M., Guze B.H., Baxter L.R., Mazziotta J.C., Phelps M.E. [18F]-fluorodeoxyglucose (FDG) and positron emission tomography (PET) in aging and dementia. A decade of studies. Eur Neurol 1989, 29(Suppl 3):16-24.
19. Jagust W.J., Bandy D., Chen K., Foster N.L., Landau S.M., Mathis C.A., Price J.C., Reiman E.M., Skovronsky D., Koeppe R.A. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 2010, 6:221-229.
20. Jagust W.J., Eberling J.L. MRI, CT, SPECT, PET: their use in diagnosing dementia. Geriatrics 1991, 46:28-35.
21. Klunk W.E., Lopresti B.J., Ikonomovic M.D., Lefterov I.M., Koldamova R.P., Abrahamson E.E., Debnath M.L., Holt D.P., Huang G.F., Shao L., DeKosky S.T., Price J.C., Mathis C.A. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 2005, 25:10598-10606.
22. Kuczynski B., Reed B., Mungas D., Weiner M., Chui H.C., Jagust W. Cognitive and anatomic contributions of metabolic decline in Alzheimer disease and cerebrovascular disease. Arch Neurol 2008, 65:650-655.
23. Leahy R.M., Qi J. Statistical approaches in quantitative positron emission tomography. Stat Comput 2000, 10:147-165.
24. Luo F, Rustay NR, Ebert U, Hradil VP, Cole TB, Llano DA, Mudd SR, Zhang Y, Fox GB, Day M (in press) Characterization of 7- and 19-month-old Tg2576 mice using multimodal in vivo imaging: limitations as a translatable model of Alzheimer's disease. Neurobiol Aging.
25. Magistretti P.J., Pellerin L. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos Trans R Soc Lond B Biol Sci 1999, 354:1155-1163.
26. Mancuso C., Scapagini G., Curro D., Giuffrida Stella A.M., De Marco C., Butterfield D.A., Calabrese V. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front Biosci 2007, 12:1107-1123.
27. Mancuso M., Calsolaro V., Orsucci D., Siciliano G., Murri L. Is there a primary role of the mitochondrial genome in Alzheimer's disease?. J Bioenerg Biomembr 2009, 41:411-416.
28. Miller G. The puzzling rise and fall of a dark-horse Alzheimer's drug. Science 2010, 327(5971):1309.
29. Mirrione M.M., Schiffer W.K., Fowler J.S., Alexoff D.L., Dewey S.L., Tsirka S.E. A novel approach for imaging brain-behavior relationships in mice reveals unexpected metabolic patterns during seizures in the absence of tissue plasminogen activator. Neuroimage 2007, 38:34-42.
30. Myers R., Hume S. Small animal PET. Eur Neuropsychopharmacol 2002, 12:545-555.
31. Norfray J.F., Provenzale J.M. Alzheimer's disease: neuropathologic findings and recent advances in imaging. AJR 2004, 182:3-13.
32. Pagani L., Eckert A. Amyloid-Beta interaction with mitochondria. Int J Alzheimers Dis 2011, 2011:925050.
33. Reivich M., Kuhl D., Wolf A., Greenberg J., Phelps M., Ido T., Casella V., Fowler J., Hoffman E., Alavi A., Som P., Sokoloff L. The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res 1979, 44:127-137.
34. Roberson E.D., Mucke L. 100 years and counting: prospects for defeating Alzheimer's disease. Science 2006, 314:781-784.
35. Sanz-Blasco S., Valero R.A., Rodriguez-Crespo I., Villalobos C., Nunez L. Mitochondrial Ca2+ overload underlies Abeta oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs. PLoS One 2008, 3:e2718.
36. Schmidt M.E., Andrews R.D., van der Ark P., Brown T., Mannaert E., Steckler T., de Hoon J., Van Laere K. Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in healthy male subjects. Psychopharmacology (Berl) 2010, 208:109-119.
37. Small G.W., Ercoli L.M., Silverman D.H., Huang S.C., Komo S., Bookheimer S.Y., Lavretsky H., Miller K., Siddarth P., Rasgon N.L., Mazziotta J.C., Saxena S., Wu H.M., Mega M.S., Cummings J.L., Saunders A.M., Pericak-Vance M.A., Roses A.D., Barrio J.R., Phelps M.E. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2000, 97:6037-6042.
38. Steele J.W., Kim S.H., Cirrito J.R., Verges D.K., Restivo J.L., Westaway D., Fraser P., Hyslop P.S., Sano M., Bezprozvanny I., Ehrlich M.E., Holtzman D.M., Gandy S. Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo. Mol Neurodegener 2009, 4:51.
39. van Marum R.J. Current and future therapy in Alzheimer's disease. Fundam Clin Pharmacol 2008, 22:265-274.
40. Wang X., Su B., Siedlak S.L., Moreira P.I., Fujioka H., Wang Y., Casadesus G., Zhu X. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci U S A 2008, 105:19318-19323.
41. Yao J., Du H., Yan S., Fang F., Wang C., Lue L.F., Guo L., Chen D., Stern D.M., Gunn Moore F.J., Xi Chen J., Arancio O., Yan S.S. Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease. J Neurosci 2011, 31(6):2313-2320.